Research, Case Studies, Publications
Malignancies are molecularly complex and become more resistant with each line of therapy. We hypothesized that offering matched, individualized combination therapies to patients with treatment-naïve, advanced cancers would be feasible and efficacious. Patients with newly diagnosed unresectable/metastatic, poorprognosis cancers were enrolled in a cross-institutional prospective study. A total of 145 patients were included in the […]
Oncologists need effective precision medicine tools to navigate the myriad of therapeutic options to best address each patient’s unique tumor profile. Described here is a digital solution, which analyzes tumor data (NGS, other), scores and ranks known and novel matching combinations of cancer drugs with molecular-level precision for decision support. All data was acquired through […]
Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer. Examples of successful matching of tumor molecular alterations to cognate drugs include: NTRK inhibitors larotrectinib and entrectinib in multiple solid tumors with NTRK fusions1,2, ROS1 inhibitors entrectinib and crizotinib in non-small cell lung cancer (NSCLC) with ROS1 alterations3,4, and the […]
Oncology is currently the largest area of clinical health expenditures for prescription drugs in the United States [1], and, based on the current pace of innovation in cancer care, anti-cancer treatment costs are only expected to increase [2]. Still, cancer remains a significant medical challenge, stubbornly resistant to conventional treatments. Further, many patients with cancer […]
SAN DIEGO, CA – June 22, 2018 – CureMatch, Inc. offers results of an artificial intelligence (AI) based cancer study at the WIN Symposium 2018 in Paris, June 25-26. CureMatch Co-founder Razelle Kurzrock, M.D. is the Organizing Committee Co-Chair of this 10th anniversary Worldwide Innovative Networking in Personalized Cancer Research event. CureMatch data scientist, Alexander […]